Vaccination is considered the most cost-effective approach to manage neosporosis, the disease caused by N. caninum. However, no commercial vaccine for neosporosis is available to date. We have previously developed an experimental mucosal vaccine for neosporosis that boosts immunity both in the gastrointestinal mucosa and systemically. The objective of this project is to improve antigen delivery and immunogenicity, by using DODAB:monoolein liposomes.
Universidade do Minho (UMinho); Instituto de Ciências Biomédicas Abel Salazar (ICBAS) da Universidade do Porto; Instituto Nacional de Investigação Agrária e Veterinária, I.P (INIAV); Instituto de Investigação e Inovação em Saúde da Universidade do Porto - Associação (i3S)
